StockNews.AI
TEVA
StockNews.AI
7 hrs

Teva Releases Q3 2025 Aide Memoire

1. Teva released its Q3 2025 Aide Memoire for investors. 2. The Aide Memoire helps in financial modeling of quarterly results. 3. Teva focuses on neuroscience, immunology, and complex generics. 4. Risks include competition, significant indebtedness, and regulatory challenges. 5. Forward-looking statements carry substantial risks and uncertainties.

4m saved
Insight
Article

FAQ

Why Neutral?

The article announces an Aide Memoire without specific financial results or guidance.

How important is it?

The document is informative but lacks new crucial data affecting stock price.

Why Short Term?

Immediate impact on investor sentiment can be expected, pending actual Q3 results.

Related Companies

PFEJNJMRK
September 25, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its website. Q3 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com. Cautionary Note Regarding Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2025, and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors” and “Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Media Inquiries TevaCommunicationsNorthAmerica@tevapharm.com Teva Investor Relations InquiriesTevaIR@Tevapharm.com

Related News